MEDA

MEDA
Clinical data
Other names	3-Methoxy-4,5-ethylenedioxyamphetamine; 5-Methoxy-3,4-ethylenedioxyamphetamine; 5-Methoxy-EDA; 5-MeO-EDA
Routes of; administration	Oral
ATC code	None;
Pharmacokinetic data
Duration of action	Unknown
Identifiers
	IUPAC name 1-(8-methoxy-2,3-dihydro-1,4-benzodioxin-6-yl)propan-2-amine;
CAS Number	23693-25-6 ;
PubChem CID	25798;
ChemSpider	24034 ;
UNII	T2DAA4TB22;
KEGG	D03376 ;
Chemical and physical data
Formula	C12H17NO3
Molar mass	223.272 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES NC(CC1=CC2=C(OCCO2)C(OC)=C1)C;
	InChI InChI=1S/C12H17NO3/c1-8(13)5-9-6-10(14-2)12-11(7-9)15-3-4-16-12/h6-8H,3-5,13H2,1-2H3 ; Key:NRVFDGZJTPCULU-UHFFFAOYSA-N ;
	(what is this?) (verify)

MEDA, also known as 3-methoxy-4,5-ethylenedioxyamphetamine or as 5-methoxy-EDA, is a chemical compound of the phenethylamine, amphetamine, and EDxx families. It is the EDxx analogue of the MDxx psychedelic and entactogen MMDA (5-methoxy-MDA). In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists MEDA's dose as greater than 200 mg orally and its duration as unknown. MEDA produced few to no effects at tested doses. The chemical synthesis of MEDA has been described. MEDA was first described in the scientific literature by Shulgin in 1964. Subsequently, it was described in greater detail by Shulgin in PiHKAL in 1991.